170 related articles for article (PubMed ID: 29416773)
1. Reactivating TP53 signaling by the novel MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma.
Arnhold V; Schmelz K; Proba J; Winkler A; Wünschel J; Toedling J; Deubzer HE; Künkele A; Eggert A; Schulte JH; Hundsdoerfer P
Oncotarget; 2018 Jan; 9(2):2304-2319. PubMed ID: 29416773
[TBL] [Abstract][Full Text] [Related]
2. Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition.
Ishizawa J; Nakamaru K; Seki T; Tazaki K; Kojima K; Chachad D; Zhao R; Heese L; Ma W; Ma MCJ; DiNardo C; Pierce S; Patel KP; Tse A; Davis RE; Rao A; Andreeff M
Cancer Res; 2018 May; 78(10):2721-2731. PubMed ID: 29490944
[TBL] [Abstract][Full Text] [Related]
3. Effect of murine double-minute 2 inhibitors in preclinical models of advanced clear cell carcinomas originating from ovaries and kidneys.
Kawata Y; Nagasaka K; Oda K; Makii C; Takeuchi M; Oki S; Honjo H; Kojima M; Miyagawa Y; Taguchi A; Tanikawa M; Sone K; Hiraike H; Matsumoto Y; Wada-Hiraike O; Ayabe T; Osuga Y; Fujii T
Cancer Sci; 2020 Oct; 111(10):3824-3834. PubMed ID: 32713096
[TBL] [Abstract][Full Text] [Related]
4. Molecular docking of DS-3032B, a mouse double minute 2 enzyme antagonist with potential for oncology treatment development.
da Mota VHS; Freire de Melo F; de Brito BB; da Silva FAF; Teixeira KN
World J Clin Oncol; 2022 Jun; 13(6):496-504. PubMed ID: 35949428
[TBL] [Abstract][Full Text] [Related]
5. Low p14ARF expression in neuroblastoma cells is associated with repressed histone mark status, and enforced expression induces growth arrest and apoptosis.
Dreidax D; Gogolin S; Schroeder C; Muth D; Brueckner LM; Hess EM; Zapatka M; Theißen J; Fischer M; Ehemann V; Schwab M; Savelyeva L; Westermann F
Hum Mol Genet; 2013 May; 22(9):1735-45. PubMed ID: 23343716
[TBL] [Abstract][Full Text] [Related]
6. In Vitro Assessment of the Role of p53 on Chemotherapy Treatments in Neuroblastoma Cell Lines.
Blanco-Luquin I; Lázcoz P; Celay J; Castresana JS; Encío IJ
Pharmaceuticals (Basel); 2021 Nov; 14(11):. PubMed ID: 34832966
[TBL] [Abstract][Full Text] [Related]
7. Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma.
Van Maerken T; Speleman F; Vermeulen J; Lambertz I; De Clercq S; De Smet E; Yigit N; Coppens V; Philippé J; De Paepe A; Marine JC; Vandesompele J
Cancer Res; 2006 Oct; 66(19):9646-55. PubMed ID: 17018622
[TBL] [Abstract][Full Text] [Related]
8. MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells.
Slack AD; Chen Z; Ludwig AD; Hicks J; Shohet JM
Cancer Res; 2007 Mar; 67(6):2448-55. PubMed ID: 17363562
[TBL] [Abstract][Full Text] [Related]
9. Targeting MDM2 for Neuroblastoma Therapy: In Vitro and In Vivo Anticancer Activity and Mechanism of Action.
Wang W; Wang X; Rajaei M; Youn JY; Zafar A; Deokar H; Buolamwini JK; Yang J; Foster JH; Zhou J; Zhang R
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33291373
[TBL] [Abstract][Full Text] [Related]
10. MDM2 as MYCN transcriptional target: implications for neuroblastoma pathogenesis.
Slack A; Lozano G; Shohet JM
Cancer Lett; 2005 Oct; 228(1-2):21-7. PubMed ID: 15927364
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of MDM2 gene expression in childhood neuroblastoma.
Inomistova MV; Svergun NM; Khranovska NM; Skachkova OV; Gorbach OI; Klymnyuk GI
Exp Oncol; 2015 Jun; 37(2):111-5. PubMed ID: 26112937
[TBL] [Abstract][Full Text] [Related]
12. Effect of low doses of actinomycin D on neuroblastoma cell lines.
Cortes CL; Veiga SR; Almacellas E; Hernández-Losa J; Ferreres JC; Kozma SC; Ambrosio S; Thomas G; Tauler A
Mol Cancer; 2016 Jan; 15():1. PubMed ID: 26728659
[TBL] [Abstract][Full Text] [Related]
13. Stable knockdown of MYCN by lentivirus-based RNAi inhibits human neuroblastoma cells growth in vitro and in vivo.
Jiang R; Xue S; Jin Z
Biochem Biophys Res Commun; 2011 Jul; 410(2):364-70. PubMed ID: 21683062
[TBL] [Abstract][Full Text] [Related]
14. MYCN concurrence with SAHA-induced cell death in human neuroblastoma cells.
Cortés C; Kozma SC; Tauler A; Ambrosio S
Cell Oncol (Dordr); 2015 Oct; 38(5):341-52. PubMed ID: 26306783
[TBL] [Abstract][Full Text] [Related]
15. Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma.
Chen L; Rousseau RF; Middleton SA; Nichols GL; Newell DR; Lunec J; Tweddle DA
Oncotarget; 2015 Apr; 6(12):10207-21. PubMed ID: 25844600
[TBL] [Abstract][Full Text] [Related]
16. Cinacalcet inhibits neuroblastoma tumor growth and upregulates cancer-testis antigens.
Rodríguez-Hernández CJ; Mateo-Lozano S; García M; Casalà C; Briansó F; Castrejón N; Rodríguez E; Suñol M; Carcaboso AM; Lavarino C; Mora J; de Torres C
Oncotarget; 2016 Mar; 7(13):16112-29. PubMed ID: 26893368
[TBL] [Abstract][Full Text] [Related]
17. p53 cellular localization and function in neuroblastoma: evidence for defective G(1) arrest despite WAF1 induction in MYCN-amplified cells.
Tweddle DA; Malcolm AJ; Cole M; Pearson AD; Lunec J
Am J Pathol; 2001 Jun; 158(6):2067-77. PubMed ID: 11395384
[TBL] [Abstract][Full Text] [Related]
18. Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas.
Verreault M; Schmitt C; Goldwirt L; Pelton K; Haidar S; Levasseur C; Guehennec J; Knoff D; Labussière M; Marie Y; Ligon AH; Mokhtari K; Hoang-Xuan K; Sanson M; Alexander BM; Wen PY; Delattre JY; Ligon KL; Idbaih A
Clin Cancer Res; 2016 Mar; 22(5):1185-96. PubMed ID: 26482041
[TBL] [Abstract][Full Text] [Related]
19. GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3.
Fabian J; Lodrini M; Oehme I; Schier MC; Thole TM; Hielscher T; Kopp-Schneider A; Opitz L; Capper D; von Deimling A; Wiegand I; Milde T; Mahlknecht U; Westermann F; Popanda O; Roels F; Hero B; Berthold F; Fischer M; Kulozik AE; Witt O; Deubzer HE
Cancer Res; 2014 May; 74(9):2604-16. PubMed ID: 24419085
[TBL] [Abstract][Full Text] [Related]
20. p19-INK4d inhibits neuroblastoma cell growth, induces differentiation and is hypermethylated and downregulated in MYCN-amplified neuroblastomas.
Dreidax D; Bannert S; Henrich KO; Schröder C; Bender S; Oakes CC; Lindner S; Schulte JH; Duffy D; Schwarzl T; Saadati M; Ehemann V; Benner A; Pfister S; Fischer M; Westermann F
Hum Mol Genet; 2014 Dec; 23(25):6826-37. PubMed ID: 25104850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
